Inhibitors of Kv1.3 channels may potentially find a clinical application in therapy of some cancer disorders characterized by an over-expression of Kv1.3 channels, such as, for example, breast and lung cancer, melanoma or chronic lymphocytic leukaemia (Jang et al. 2009, 2011; Leanza et al. 2012, 2013). Here, KCNA3 is linked to cancer.